Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial
ascopubs.org/doi/10.1200/...
#JCO #JCORapidCommunication #JCOJournals
0
0
0
0